With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The 300 companies on this year’s list brought in over $12.6 trillion in revenue for the latest 12 months, with the median revenue figure at $22 billion.

America's Most Innovative Companies

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 200 companies on this list are transforming industries from the inside out.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

The pharmaceutical and medical equipment company makes products that aid in the treatment of health conditions such as kidney disease and hemophilia.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-282-Baxter-International

This Deerfield, Ill. company makes devices and other products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

This year's Fortune 500 marks the 62nd running of the list.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

World's Most Admired Companies

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Fortune Global 500

Sector

Culture rank

Process rank

Product rank

Years on list

Previous rank

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Through its subsidiaries, Baxter provides a portfolio of health care products in the U.S. through three segments: medical products and therapies, health care systems and technologies, and pharmaceuticals. Founded in 1931 with headquarters in Deerfield, Ill., it operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Baxter International (BAX): Company Profile, Stock Price, News, Rankings

legacy

Baxter International

baxter international

Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter twenty twenty five Earnings Conference Call. Your lines will remain in a listen only mode until the question and answer segment of today's call. Please press star then zero on your touch tone phone. As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission.

If you have any objections, please disconnect at this time. I would now like to turn the call over to Ms. Claire Trackman, Senior Vice President, Chief Investor Relations Officer at Baxter International. Ms. Trackman, you may begin.

Good morning, and welcome to our first quarter twenty twenty five earnings conference call. Joining me today are Brian Schafer, Baxter's Chair and Interim Chief Executive Officer Joel Grade, Baxter's Executive Vice President and Chief Financial Officer and Heather Knight, Baxter's Chief Operating Officer. On the call this morning, we will be discussing Baxter's first quarter twenty twenty five results along with our financial outlook for the second quarter and full year 2025. With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook for the second quarter and full year 2025, the anticipated impact of our strategic actions, the potential impact of various regulatory and operational matters in the global macroeconomic environment, including new and proposed tariffs on our results of operations, contain forward looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations.

Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially. In addition, on today's call, non GAAP financial measures will be used to help investors understand Factors' ongoing business performance. A reconciliation of certain non GAAP financial measures being discussed today to the comparable GAAP financial measures is included in the accompanying investor presentation and available in our earnings release issued this morning, both of which are available on our website. As a reminder, continuing operations excludes Baxter's KidneyCare business, which is now reported as discontinued operations. Now I'd like to turn the call over to Brent.

Thanks, Claire, and good morning, everyone. Thank you for joining us. Our results for the first quarter reflect the building momentum of our strategic transformation journey and the hard work of our Baxter colleagues globally. As you saw in this morning's press release, our first quarter performance for continuing operations exceeded our previously issued guidance on both the top and bottom line. We're leveraging our verticalized operating model to create a more agile focused product portfolio and advance innovation, improve execution and drive profitable growth.

First quarter sales from continuing operations grew 5% on a reported and operational basis. As a reminder, continuing operations exclude the impact of our Kidney Care business, which was acquired by Carlyle on 01/31/2025. Sales rose in all three of Baxter's continuing segments with performance in Medical Products and Therapies and Healthcare Systems and Technologies coming in ahead of expectations. Heather and Joel will share more on individual segment results later in the call. On the bottom line, adjusted earnings per share from continuing operations were $0.55 These results were fueled by top line performance, our continued emphasis on driving operational efficiency and a benefit from lower non operational expense.

We're pleased with our strong Q1 performance and confident in our strategic trajectory. At

time, we're cognizant of the volatility that is present in the global macro environment and the resulting uncertainty that has been created in the marketplace. We, like others, are keenly focused on evaluating and working to address the impact of newly enacted global tariffs and future potential tariffs as well as a range of other interrelated factors. As you're all aware, this remains an evolving and fluid situation. Joe will walk you through our key assumptions as they relate to our financial outlook for the remainder of this year and also how we plan to mitigate a portion of these impacts. To be clear, we remain positive about our opportunities to accelerate sales growth and expand margins.

We continue to build on the strengths of our operating model and a reinvigorated profile. And as always, we benefit from our durable portfolio of medically essential products, which has served as the underlying foundation of our strength for decades. Finally, I want to address a topic that I'm certain is on your mind, which is the identification of Baxter's next permanent CEO. While I'm not able to provide a detailed update, I can confirm that the search process is active and well underway, with the board being assisted by a leading search firm in these efforts. As I shared previously, the Board is moving expeditiously but also deliberately to make sure we identify the right candidate to make the most of this opportunity to harness the potential our employees have helped create.

We will, of course, keep our stakeholders updated on new developments as we are able to share them. In closing, I want to recognize our global team for their dedication to our mission and outstanding contributions to Q1 performance. And with that, I'll turn it over to Heather for a closer look at performance by segment.

Thanks, Brent, and welcome, everyone. I'm pleased to be here with you this morning to discuss our first quarter results. I'm going to walk through our sales performance in the quarter and then we'll hand it over to Joel to walk through performance across the rest of the P and L along with our financial outlook for the second quarter and full year 2025. Before I begin discussion, I want to provide a reminder that results discussed on today's call will reference operational growth, which as stated last quarter when providing guidance, excludes the impact of foreign exchange, MSA revenues from Bantiv and the planned exit of IV Solutions from China. As Brent referenced and as you've seen from our release, all three Baxter segments delivered year over year growth for the quarter at both reported and operational rates helping fuel company wide top line outperformance.

First quarter twenty twenty five global sales from continuing operations totaled $2,630,000,000 and increased 5% on both a reported basis and operational basis. This compared favorably to our previous guidance, which called for sales to increase 3% to 4% on a reported basis and approximately 4% on an operational basis. Outperformance in the quarter was led by our HST segment with particular strength in our Care and Connectivity Solutions division along with better than expected sales in MPT. Now I'll walk through our results by reportable segments. Again, regarding sales growth will reflect growth on an operational basis at constant currency rates.

Sales in our Medical Products and Therapies or MPT segment were $1,300,000,000 increasing 6% in the quarter and came in ahead of expectations. Within MPT, first quarter sales from our Infusion Therapies and Technologies division totaled $994,000,000 and increased 6%. Sales in the quarter benefited from double digit growth for our U. S. Infusion systems portfolio as the rollout of our Novum IQ pump platform continues.

Nutrition sales in the quarter advanced mid single digits globally, reflecting strong growth in The U. S. Due to the continued progress we are experiencing in alternate sites for this business as well as improved supply for certain products that resulted in the clearance of backorders. We also realized low single digit growth for IV Solutions. As we noted on the first quarter call, thanks to the team's stellar recovery efforts, production at our North Cove IV Solutions facility is back to pre hurricane levels following the impact of Hurricane Helene.

We are now focused on replenishing inventory and making continued progress on allocations for our customers. We expect to be on virtually all product allocations this month. IV Solutions sales in the quarter reflected continued conservation of fluids at hospitals across The U. S. While the network fully recovers.

Our current outlook reflects our expectation that hospitals will continue to conserve fluids in the near term, but that utilization levels will improve particularly as our allocations are removed and The U. S. Supply returns to normal levels. During the first quarter, we did see some distributors begin to rebuild their inventory levels, which helped to offset the impact from the conservation efforts. Our original expectation was that these rebuilds would likely occur more in the second quarter.

Sales in Advanced Surgery totaled $268,000,000 and grew 4% globally. Results in the quarter reflected solid growth outside The U. S. Due to increased demand for our hemostats and sealants and the timing of sales to distributors. Sales in The U.

S. Reflected one less billing day as compared to the prior year period. In addition, the prior year period reflected the benefit of a back order clearance for one of our Hemostat products. In Healthcare Systems and Technologies or HST, sales in the quarter were above expectations and totaled $7.00 $4,000,000 increasing 6%. Within the HST segment, sales in the quarter for our Care and Connectivity Solutions or CCS division were $427,000,000 advancing 7% globally.

Performance in the quarter was driven by 14% growth in The U. S. For CCS due to continued momentum in our Patient Support Systems or PSS business, which once again delivered strong growth and reflected a benefit from competitive wins in both our MedSurg and ICU product lines as well as upgrades for existing customers. Total U. S.

Capital orders for CCS rose 20 in the quarter, creating a healthy backlog to support future growth for this division. To date, we have not seen a slowdown in U. S. Capital hospital spending, but in light of the macroeconomic uncertainty, we are closely monitoring the situation. Our focus remains on highlighting the benefits of our broad portfolio and the enhanced digital capabilities we have added to improve workflow efficiency.

Performance for this division was partially offset by weaker sales outside The U. S. Importantly, we did see capital orders pick up internationally and these are anticipated to contribute to growth over the course of the year. Frontline Care sales for quarter were $277,000,000 and increased 5%. Performance in the quarter reflected a favorable comparison as well as continued signs of stabilization of the primary care market in The U.

S. Moving to our Pharmaceutical segment, sales in the quarter totaled $581,000,000 increasing 3%. First quarter sales within injectables and anesthesia of $335,000,000 grew 4%. Performance in the quarter reflected mid single digit growth in our specialty injectables portfolio driven by strong international growth reflecting a government order and increased demand. This performance was partially offset by lower sales of anesthesia in the quarter.

Our expectation is that the anesthesia business will begin to stabilize and the rate of decline for this business will start to slow. Drug compounding grew 2% and reflected a difficult comparison to the prior year period. And in other sales, which represents sales not allocated to a segment and primarily includes sales of products and services provided directly through certain manufacturing facilities were $15,000,000 in the quarter. During the quarter, MSA revenue from Vantiv totaled $63,000,000 These sales are not reflected in our operational growth, but are included in our reported growth for the quarter. Before turning it over to Joel, I want to take a step back.

Looking holistically, our strength across the segments reflects both the power and the trajectory of our newly defined enterprise. Our confidence and our future potential remains high and we are committed to executing on our strategic objectives even amid a more dynamic global macroeconomic environment. I'm confident we'll navigate this uncertainty just as we always do with the support of our 38,000 colleagues across the globe and with our mission to save and sustain lives helping define our path forward. Now I'll pass it over to Joel who will discuss performance down the rest of the P and L along with our updated financial outlook. Joel?

Thanks, Heather, and good morning, everyone. As my colleagues mentioned, we are pleased with our first quarter results, which came in ahead of our expectations on both the top and bottom lines. Before I begin, I want to highlight a point that both Brent and Heather referenced. As we're all aware, we now face a more dynamic global macroeconomic environment, which has created a level of uncertainty for everyone, including our customers. We remain squarely focused on addressing the needs of our customers through a broad portfolio of medically essential products and evaluating opportunities to better optimize our supply chain network in light of new tariffs with some activities already underway.

Importantly, we remain committed to accelerating our investments in innovation, focused on bringing products to the marketplace that solve the problems that our customers face and help redefine healthcare delivery. Importantly, we will not compromise on our efforts to thoughtfully accelerate innovation in targeted areas of the business as this is critical to support our future growth aspirations. Starting with the bottom line, first quarter adjusted earnings per share from continuing operations were $0.55 per share and came in ahead of our prior guidance of $0.47 to $0.50 per share driven by the favorable top line results, lower than expected SG and A expenses and a benefit from TSA income and other reimbursements. In addition, our tax rate and other non operational items came in favorable to our expectations, which more than offset a negative impact from foreign exchange. Before more specifically addressing the rest of the P and L results, I want to make some comments regarding our continuing operations reporting.

As a reminder, prior to the close of the Vantib deal, corporate costs that had previously been allocated to the Kidney Care segment that would not convey with the Kidney Care business in the sale were reported in unallocated corporate costs. Post close, these costs are now allocated to each of our segments along with income from our transition services agreements or TSAs as well as cost containment initiatives the company is in the process of undertaking. Our goal remains to fully offset the impact of these stranded costs and loss of TSA income by the end of twenty twenty seven. In addition, during the quarter, we reclassified certain functional expenses to cost of goods sold from SG and A following the completion of the sale of our Kidney Care business. These functional costs were previously recorded in SG and A and support manufacturing and are now classified as indirect costs subject to inventory capitalization and recorded in cost of sales when sold.

First quarter adjusted gross margin from continuing operations was 41.8%, a decrease of 160 basis points compared to the prior year. The year over year decline reflected the impact of NSA revenues from Vantib and higher expenses related to planning and fulfillment. First quarter adjusted SG and A from continuing operations totaled $6.00 $8,000,000 or 23.2 percent as a percentage of sales, a decrease of three ten basis points from the prior year period. This year over year decrease reflects the benefit from the reclassification of functional costs along with lower stock compensation expenses in the quarter and continued disciplined expense management. Adjusted R and D spending from continuing operations in the quarter totaled $138,000,000 and represented 5.3% as a percentage of sales, an increase of 50 basis points compared to the prior year period and reflects our continued investments in advancing new products across the portfolio and bringing innovation to patients across our segments.

TSA income and other reimbursements totaled $40,000,000 in the quarter. This came in higher than expected and reflected increased levels of support currently required by Vantiv. The associated expenses are reflected in other lines of the P and L. These factors resulted in an adjusted operating margin of 14.9% on a continuing operations basis, improving two sixty basis points compared to the prior year period. This performance reflects continued focus on operational execution as well as the benefit of TSA income and other reimbursements from Vantiv.

Taking a look at adjusted operating margin by each reportable segment. MPC's adjusted operating margin for the quarter was 19.3% increasing 80 basis points over the prior year period and reflecting positive pricing in the quarter partially offset by elevated costs as we continue to improve volumes at Northcove and experience higher planning and fulfillment costs. TSA income contributed to positive performance in the quarter. HST first quarter adjusted operating margins of 13.2%, a three twenty basis point improvement from the prior year, driven primarily by improved top line performance. TSA income also contributed to performance and helped to offset increased corporate allocation expenses.

Pharmaceuticals adjusted operating margins were 10.8% for the quarter, decreasing two seventy basis points compared to the prior year. These results reflect certain one time expenses realized in the quarter and an increase in corporate allocations. These expenses were partially offset by TSA income. Net interest expense from continuing operations totaled $64,000,000 in the quarter, a decrease of $14,000,000 versus the prior year period reflecting lower interest expense following the pay down of existing debt with proceeds from the sale of Antib. Adjusted other non operating income totaled $17,000,000 in the quarter compared to income of $9,000,000 in the prior year period, primarily reflecting lower losses from foreign exchange balance sheet accounts.

The continuing operations adjusted tax rate for the quarter was 17.4% benefiting from a strategic use of select tax attributes as we optimize our global structure following the sale of KidneyCare. And as previously mentioned, adjusted earnings from continuing operations were $0.55 per share for the quarter and increased 53% versus the prior year. Contributions to earnings included improved commercial performance, positive pricing, the receipt of TSA income and other reimbursements as well as the benefit of lower expenses from non operational items including interest and tax. Let me conclude my remarks by discussing our outlook for the full year 2025 and the second quarter of twenty twenty five including some key assumptions underpinning the guidance. For full year 2025, Baxter expects total sales growth of 7% to 8% on a reported basis.

This guidance reflects current foreign exchange rates which are expected to minimally impact growth on the top line. This is an increase relative to our prior guidance which had assumed that foreign exchange would negatively impact sales by approximately 200 basis points. In addition, our reported sales guidance includes the contribution of approximately $310,000,000 of anticipated MSA revenues from Vantib down slightly from our original expectations of $345,000,000 Operationally, Baxter continues to expect sales growth of 4% to 5%. As a reminder, this guidance excludes the impact of foreign exchange, MSA revenues and the planned exit of IV Solutions in China. The negative impact from exiting the IV Solutions business in China continues to be approximately 50 basis points to growth.

Operational sales guidance for the full year by reportable segment is as follows. For MPT, we continue to expect sales to increase approximately 5% driven by strength in our Infusion Systems business, positive pricing and other underlying business momentum. As mentioned earlier, we do expect IV Solutions growth to improve as we remove allocations and some of their conservation efforts. This guidance excludes the impact of exiting the IV Solutions market in China, which is estimated to impact sales growth by 100 basis points. We continue to expect sales in our HST segment to increase approximately 3%.

While we are very pleased with the building momentum and healthy backlog we have built in HST, we will continue to closely monitor the capital environment for any changes to hospital spending expectations. We continue to expect pharmaceuticals to increase approximately 5% to 6%. Before turning to our outlook for other P and L line items, I want to provide some thoughts regarding our assumptions around tariffs. Our updated guidance now includes the estimated impact from tariffs based on the current proposals enacted and assumes a reversion back to original proposed tariff rates following the ninety day suspension. In addition, our guidance does take into account that we are able to mitigate a portion of these impacts.

In general, Baxter strives to make where we sell and buy where we make as part of our broader integrated supply chain approach. This allows us to deliver our products and solutions around the world with greater control and visibility to our operations. Currently, majority of Baxter's products sold in The U. S. Are manufactured in The U.

S. And made largely from U. S.-made components. However, international procurement is part of our business operations and as such we are impacted from The US and retaliatory tariffs that have been issued. We plan to take several actions to help minimize the impacts related to tariffs.

Some of these actions will be able to be realized more near term to help mitigate the impact in 2025 and others will require more time to be implemented, but will help offset the impact in future years. Some of these mitigation opportunities include actively communicating with and assessing our supplier base to identify risks and work to implement mitigations, which could include carrying additional inventory and identifying alternative suppliers or manufacturing locations identifying alternative shipping routes for suppliers and finished goods to help minimize the overall impact assessing targeted pricing actions and finally, continuing to work closely with our trade association partners in various countries to advocate for possible exemptions. Taking all this into account, we estimate the net impact to our results from tariffs is approximately 60,000,000 to $70,000,000 in 2025. Additionally, based on our standard roll out period, we expect to see the majority of the tariff impact in the second half of the year. I'd note that while China represents a very small percentage of our total sales, given the magnitude of the tariffs that have been enacted between the two countries, these tariffs now account for nearly half of the total impact.

At this time, our tariff assumptions do not reflect any potential tariffs related to pharmaceutical products. One other item I'd like to highlight is that while current foreign exchange rates are expected to benefit top line relative to prior guidance, they do negatively impact our adjusted operating margins and adjusted earnings per share, which is driven by our current infrastructure footprint that remains post sale of Vantiv. We have plans over time to optimize our global footprint. Inclusive of these factors and underlying business performance, we now expect full year adjusted operating margin from continuing operations between 16% to 16.5%. TSA income and other reimbursements are now expected to range between $140,000,000 to $150,000,000 This increase reflects incremental services provided to Vantiv with the related expenses reflected in the other lines of the P and L.

We expect our non operating expenses, which include net interest expense and other income and expense to total between $220,000,000 to $240,000,000 On a continuing operations basis, we anticipate a full year tax rate of approximately 19 to 19.5%. We expect our diluted share count to average approximately $515,000,000 shares for the year, which does not contemplate any share repurchases. Based on all these factors, we are increasing the low end of our prior guidance range and now anticipate full year adjusted earnings on a continuing operations basis of $2.47 to $2.55 per diluted share. Specific to the second quarter of twenty twenty five, we expect continuing operations sales growth of approximately 4% to 5% on a reported basis and 1% to 2% on an operational basis. For the second quarter, foreign exchange is expected to positively impact the top line by approximately 50 basis points and MSA revenues are expected to total approximately $80,000,000 The China IV Solutions exit is expected to impact top line growth by approximately 70 basis points in the second quarter.

On a continuing operations basis, we expect adjusted earnings per share of $0.59 to $0.63 With that, we can now open up the call for Q and A.

Thank you. We will now begin the question and answer session. Press star then 1 a second time. If you are using a speakerphone, please lift the handset to ask your question. So that we may be respectful of everyone's time, please limit your comments to one question with one follow-up question if necessary.

We appreciate everyone's patience and would like to provide as many of you as possible the opportunity to ask a question. We will pause for a moment while the list is being compiled. I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter International website for sixty days at www.baxter.com. Our first question comes from Joanne Wuensch of Citi. Your question please.

Good morning. It's Joanne Wuensch and very nice quarter and start to the year. I have to ask the obligatory tariff question, specifically what you are pulling back on or managing to offset some of the headwinds? And then how should we think about 2026? Should we just annualize your run rate that you gave for 2025?

And then I'll give you my second question upfront. The H2SP business, I think this was your strongest quarter since 2023. How should we think about that recovery and the sustainability? Thank you.

Thanks, Joanna. Good morning. It's Joel. I'll take the first part and then I'll pass it over to Heather for the second. So from a tariff perspective, certainly, we do have a number of mitigation activities, some of which are underway already, others which are continuing to be developed.

But also from a timing perspective, again, there's going to be some spread on that. But I'd group it into a couple of things, one from a supply chain perspective, certainly some optimization activities around negotiating with suppliers, finding potential alternative supply, whether it's different suppliers or we have over different places. Looking to do things, we're optimizing freight, optimizing supply. Think about routes and whether we need to go from one country to another to another or we can go direct. Again, there are certain things we're looking to really do to optimize those things.

We're certainly from a pricing standpoint, I'd say it's very targeted. There's some very targeted areas around that, not a broad strategy there necessarily. But then from and then finally, just from a continuing to seek additional exemptions working with our government team and then the various countries we operate in and certainly in our industry groups to find different ways to potentially have exemptions for other products. So those are some of the things I'd say broadly are the things we're focused on from a mitigation perspective. And I guess what I'd say from 2026, the way I would look at that again is I think it's probably fair, although as I said in my comments, the mitigation impacts aren't necessarily all in place now.

And so those things are going to phase. And so the impact, the litigation activities will be phasing as we go into next year as well. So I'll for the second part, I'll pass that over to Heather.

Yes. Hi. Good morning, Joanne, and thanks for the question, and thanks for acknowledging the HST performance. We're really pleased with the first quarter, and our teams have been working really hard with our customers. So we're pleased overall with the beat.

It was broad based and across all of our businesses really exceeding expectations, particularly around the building momentum that we're seeing across The U. S. So we've got a healthy backlog, particularly in the PFS business, as I mentioned, strong order growth and a lot of competitive account wins. So the commercial excellence that we talked about last year and customer programs are starting to pay off as we've managed the supply recovery that we talked about last year. While we haven't seen any slowdown today in the capital environment, we are monitoring the situation, but didn't feel even based on the momentum that it was prudent to just raise guidance in HST this year, but more maintained.

But overall, I would say we're happy with the momentum of the team and the business and the leadership across the organization. So thanks for the question.

Yeah. And actually, if I could just add one thing, Heather, to that. Even in the FLC side, I think one of the things that was actually a good impact on this quarter was a balanced growth between both the CCS and Frontline Care. And I think the we saw some stabilization, I'd say, in the primary care markets. On the SLC side, we had we also had less headwinds in 'twenty five and 'twenty four.

We kind of talked about that heading into the year. Our backlogs are closer to normal levels in SLC. And then obviously, we also had some favorable year over year comparisons that we're up against. But just the one I add to Heather's point there, think, again, it really was not only the CCS part, which we're really pleased with, but also again balanced really across that portfolio.

David Roman of Goldman Sachs is on the line with a question. Please state your question.

Thank you. Good morning, Heather, Joel and Claire. Wanted just to start here on the IV side. Hospitals have been pretty successful in implementing conservation programs, and we haven't seen much of a disruption, at least it seems from the outside in hospital operations or elective procedure volumes. So as you remove hospitals from allocation, can you maybe help us frame what you expect the impact to be to your business?

And then also, if you think hospitals will return to pre hurricane inventory management levels or there's something that may have more structurally changed in how they approach managing this particular supply line? And then I have a follow-up on tariffs.

Sure. Hi, David. Good morning. It's Heather. So I'll start.

So when you think about conservation, it's really hospitals. There's a subset of hospitals that are conserving right now. And we still assume in our outlook that there will be conservation as we exit the year, in the 10% to 12% range is what we're assuming when you exit the year. So that's broadly for The U. S.

So there are many customers that are actually using more solutions than pre hurricane levels. So it's definitely not a one size fits all. But we are assuming that conservation continues that there's been some adjustment in practice and we saw some of that with Hurricane Maria as well. It sort of took about a year or so for that utilization to continue. So we baked that into the forecast.

I think it's important to note when you think about MPT for the half, we worked really hard to make sure that we could stabilize our customers with inventory and IV. So the timing of how we manage that in the half, we recovered really quickly and we're focused in Q1 on getting inventory back to good with our customers and with distributors. But the half, when you look at it, is really largely in line with our expectations. So that is driving how we're thinking about MPT, particularly for the first half. But I would say that customers now are starting to really think about safety stock in an area like IVs that is critical to health care and overall very happy with the recovery out of North Cove.

And I'm really proud of our teams and the work that they did to make sure that we could get products to patients as quickly as possible. So that drove some of the overachievement in the beach and MPT, but largely have baked in conservation to the forecast for the rest of the year. Thanks, David.

Alright. Great. Thank you. Yeah. Thank you for that detail.

I I I think, Joel, on on the tariff side, there is a significant amount of confusion, and I would say your misinformation entered the market on your tariff exposure the past several weeks. So are you I understand that we don't know what the pharma tariff may or may not be, but can you give us any parameters, to frame how to think about that? Because if a pharma tariff is announced between now and when you report earnings again, we're all going to try to quantify it. So maybe help us understand where the exposure is, how much do you import in finished goods from the Clarus plant? I think it's very small, but there's obviously an API impact.

Maybe just walk us through the moving parts there and the level of potential exposure.

Yes. David, thanks. I mean, first of all, to answer your Clarus question, that's a very small thing. Again, that's not a material impact there. I guess I'm not sure exactly what to give you there other than we're just going to be continuing to wait and see how this develops.

I mean, we're certainly some of the things we're thinking through from a mitigation perspective obviously apply there as well. And so we're trying to be very proactive and thinking about sort of the scenario planning around that. At this point, though, obviously, it's still pretty up in the air where that's going to go or how that's going to land and what, if any, types of exemptions may be part of that. And so certainly, again, as I mentioned earlier, the part of our industry conversations with governments are around the ability to have some of these type of product exemptions. And obviously, for us, being generics versus some of the larger brand, obviously, that is a sizable more sizable impact for us from a margin perspective potentially.

But again, nothing really to say other than we're trying to be very proactive thinking about scenario planning and what we're doing to mitigate, but really nothing else to add at this point.

Travis Steed of BofA Securities is on the line with a question. Please state your question.

Hi. First, I wanted to ask a margin question, both kind of short term and long term. First on the gross margin, there's a little bit of a delta between your gross margin and consensus. I assume that's the reclassified certain functional expenses from COGS to SG and A. So I wanted to touch on that, and kind of understand when you kind of think about TSA and MSAs over the course of this year and next year, how to think about the margin impact?

And then longer term, kind of the path back to that kind of pre COVID-nineteen percent operating margins for this business?

Sure. Thanks, Travis. It's Hal, I'll take that. A couple of things. From the margin gross margin perspective question you had, it really comes down so you said it's the reclassification is a part of this.

The dilution from MFA income is also a sizable part of that. And then just other things that I would say, we're still recovering from some of the planning and fulfillment costs that occurred in North Cove that are also contributing to our gross margins this particular quarter. So I think those are really some of the main puts and takes as it relates to the gross margin perspective. Again, some of that, particularly the last one that I talked about, we do anticipate some of that mitigating over the course of the year. The long term path from a TSA and MSA perspective, again, our anticipation is that from a TSA perspective, as I've said previously, our we anticipate those being part of our world for certainly a good eighteen to twenty four months.

Now again, we're certainly planning for the phasing off of those things where we have a lot of cost containment activities that are happening today that are happening in preparation for the TSAs falling off. Certainly, the anticipation of the TSAs being where they are this year, we talked about a 40 impact on a net basis from a stranded cost perspective. I think that's something you should still expect throughout the course of this year. And MSAs as well, we did talk about the fact that the MSA income is slightly less than we had anticipated, which therefore has again a slightly less dilutive impact from a margin perspective. But I think the $310,000,000 number we talked about, this will eventually phase out, but that's something that will be in here over certainly for

I would say the long term path towards margin expansion it really comes down to a number of different items. Starting with just our continued opportunity to continue to have our, again, strong growth. We've talked about the ideas of how we plan to invest in innovation. And so new product launches are certainly an element of how over time we'll continue to expand from a margin perspective. Pricing, certainly, we see some of that this year.

Obviously, on an ongoing basis, will have on a kind of a normal year a little lesser impact, but then again we do have another some GPO renegotiation coming up in a couple of years. So there may be some pricing impact there as well. From a product mix standpoint and a, again, I'll call it business mix perspective is another area

that we continue to see opportunities from a margin expansion, again, selling more of those areas that generate higher margins.

And then finally, things like our margin improvement programs along the way that we continue to have in our supply chain. These are areas that again are continuous drivers of our margin expansion in addition to obviously between now and 2027, there will be full removal, if you will, of our stranded costs that are left over from the kidney. And so that's a few of the areas of our puts

and takes as it relates to margins and how we see that opportunity to expand as we go forward.

Vijay Kumar of Evercore ISI is online with a question. Please state your question.

Hey guys, thanks for taking my question and congrats on the nice execution here. Jill, maybe my first one for you on the guidance kind of question. You look at second quarter, '1 percent to 2% for core Baxter, that's a three fifty basis points decel at the midpoint from Q1 levels. I think your comps get a little bit harder, a couple of hundred basis points. So what's driving this deceleration in the second quarter in the operating margins?

So prior sixteen point five percent, did that change because of tariffs?

Yes. Thanks for the question. So from a revenue standpoint in Q2, it's really a couple of things that are driving that outcome. One, as we've talked about some of the conservation that is happening in some of

the hospital systems from an IV fluid perspective is one of

the key drivers. This is one of the things we've talked about and we've got a preview that we anticipated happening for a while and we're seeing some of that. And certainly that's one of the key drivers of that impact in the second quarter. I think another one part I would just say is, I guess, I'll call it a degree of conservatism as it relates to some of the performance from an HST perspective. Obviously, as we've talked about, we're pleased with the momentum in that business.

We're pleased with the outlook on the CCS side and some of the stabilization impact on Frontline Care. But I guess I would just say there is an element to this that is continuing to just be have some level of conservatism in that as it relates to that business in particular. But certainly, are some of the main drivers of the change from a Q1 to Q2 perspective. The other thing I would point out is that while that is the case, obviously, some of the overperformance in Q1 when you factor in then a little bit of the impact we discussed in Q2. Our H1 for the most part, comes in right around where we had expected.

So the so while there was a little bit of a shift in distribution between the quarters, the first half of the year is something that we

certainly we're pretty consistent with how we had anticipated it coming in.

Your second question, yes, the operating margin impact that you're referencing was related to tariffs as well as some of

that we talked about from a foreign exchange perspective. Again, while we have some positive impact on the top line of FX, we actually do have a dilutive impact, I'll call it, on the bottom line as it relates to foreign exchange. This relates to some of the operations that we still have outside The U. S. Again, would say it's still a remnant from the Vantage business that we have.

This is over time, plans to continue to optimize our infrastructure in our business, OUS. But that's the other part of it that I would say is driving some of that impact as well.

Understood. And maybe, Heather, one follow-up for you on on this known, very strong numbers. The the, can you just remind us for context, like, what's been share gains for the past few quarters? Has it accelerated? And if these trends sustain, what's the downstream implication from a consumables and IV fluids standpoint?

Yes. Hi, Vijay. I'll tackle the first one first question on Novum. So the backlog and pipeline on Novum is strong. So yes, we have taken market share in the low single digit range already.

So there's good momentum in the Novum franchise, not just for the launch. Nobum has been in the market now less than a year, but also the innovation pipeline coming behind it is pretty robust and rich. So we're excited and our customers are excited about partnering with us around Nobum. A lot of the pumps in the market have a decade plus old. So we're bringing new technology to the market with smarter, more sophisticated capabilities on interoperability with digital suites that are going to follow to supplement that launch.

Baxter International (BAX) Q1 2025 Earnings Call Transcript

Company Participants